CA1218601A - Sucralfate suspension - Google Patents
Sucralfate suspensionInfo
- Publication number
- CA1218601A CA1218601A CA000461033A CA461033A CA1218601A CA 1218601 A CA1218601 A CA 1218601A CA 000461033 A CA000461033 A CA 000461033A CA 461033 A CA461033 A CA 461033A CA 1218601 A CA1218601 A CA 1218601A
- Authority
- CA
- Canada
- Prior art keywords
- sucralfate
- suspension
- agents
- suspending agent
- pharmaceutically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960004291 sucralfate Drugs 0.000 title claims abstract description 35
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 title claims abstract description 35
- 239000000725 suspension Substances 0.000 title claims abstract description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000000375 suspending agent Substances 0.000 claims abstract description 10
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 8
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 6
- 229960000443 hydrochloric acid Drugs 0.000 claims description 6
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- -1 disac-charide compound Chemical class 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000007971 pharmaceutical suspension Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 abstract description 14
- 210000001198 duodenum Anatomy 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 abstract description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 7
- 238000009472 formulation Methods 0.000 abstract description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 5
- 239000002518 antifoaming agent Substances 0.000 abstract description 5
- 239000000600 sorbitol Substances 0.000 abstract description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract description 4
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 abstract description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 abstract description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 abstract description 4
- 229960002216 methylparaben Drugs 0.000 abstract description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract description 4
- 239000008108 microcrystalline cellulose Substances 0.000 abstract description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract description 4
- 239000003755 preservative agent Substances 0.000 abstract description 4
- 229940083037 simethicone Drugs 0.000 abstract description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract description 3
- 239000000796 flavoring agent Substances 0.000 abstract description 3
- 235000019634 flavors Nutrition 0.000 abstract description 3
- 239000003086 colorant Substances 0.000 abstract description 2
- 239000000839 emulsion Substances 0.000 abstract description 2
- 230000002335 preservative effect Effects 0.000 abstract description 2
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 abstract 1
- 229960003730 methylcellulose (4000 cps) Drugs 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 description 10
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 210000003238 esophagus Anatomy 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 229940037003 alum Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N beta-D-galacturonic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
SUCRALFATE SUSPENSION
Abstract of the Disclosure This invention provides a suspension effective for the treatment of ulcerative conditions from the mouth to the duodenum. The suspension comprises a pharmaceutically ef-fective amount of a disaccharide polysulfate-aluminum com-pound, such as sucralfate and a pharmaceutically acceptable suspending agent and is capable of forming a viscous mass when added to 0,5 N hydrochloric acid. The suspension may additionally contain bodying agents, preservatives, antifoam agents, flavors and coloring agents.
A preferred formulation is an aqueous suspension containing 10% sucralfate and employing a suspending agent composed of 1% microcrystalline cellulose, 0.2% colloidal silicon dioxide, and 0.25% methylcellulose (4000 cps), in combination with 20% sorbitol 70% and 9.9% glycerin 99.5% as bodying agents, 0.2% methylparaben as a preservative and 0.3% simethicone 30% emulsion as an antifoaming agent.
Abstract of the Disclosure This invention provides a suspension effective for the treatment of ulcerative conditions from the mouth to the duodenum. The suspension comprises a pharmaceutically ef-fective amount of a disaccharide polysulfate-aluminum com-pound, such as sucralfate and a pharmaceutically acceptable suspending agent and is capable of forming a viscous mass when added to 0,5 N hydrochloric acid. The suspension may additionally contain bodying agents, preservatives, antifoam agents, flavors and coloring agents.
A preferred formulation is an aqueous suspension containing 10% sucralfate and employing a suspending agent composed of 1% microcrystalline cellulose, 0.2% colloidal silicon dioxide, and 0.25% methylcellulose (4000 cps), in combination with 20% sorbitol 70% and 9.9% glycerin 99.5% as bodying agents, 0.2% methylparaben as a preservative and 0.3% simethicone 30% emulsion as an antifoaming agent.
Description
6G ~
1 SUCRAL~ATE SUSPENSION
Back~round of the Invention a~ Field of the Invention Sucralfate is a disaccharide polysulfate aluminum ~ompound useful in ~he trea~ment of duodenal ulsers. This invention provides a suspension of sucralfate by means of which sucralfate is made available for treatment of ulcer-, ~tive conditions of the esophagus and stomach, as well as the duodenum.
b) State of the Art Sucralfate is a disaccharide polysulfate aluminum compound which is covered by United States Patent No~
3,432,489. Sucralfate is believed to be 3,4,5,6-tetra-~polyhydroxyaluminum)-alpha~D-glycopyranosyl 1~ sulfate-2,3,4,5-tetra-(polyhydroxyaluminum)-beta-D-fructo-furanoside sulfate.
Sucralfate is useful in the treatment of ulcers in the duodenum. Sucralfate is available in tablets which . disintegrate rapidly in the stomach releasing the sucralfate , for reaction wlth ulcer tissues in the duodenum.
To date, sucralfate has not been available in a form which would render it effective in treatment of ulcer-ative conditions of the mouth, esophagus or stomachO The l; difficulty in formulating a sucralfate composition for ,, treatment of such sites has characteristically been due to the inability to supply sucralfate in a form which would be available at those sites. Formulations, including liquid formulations, have been tried without success.
~ It has now been discovered that sulcralfate is available for treatment of ulcer tissues in the esophagus 1 and stomach, as well as the duodenum, when formulated as a suspension which forms a sticky gel-like or ~acky viscous mass which settles ~o the bottom of ~he reaction vessel when added to 0.2 to 1.0 N hydrochloric acid.
Summary of he Invention This invention provides a sucralfate suspension effective for the treatment of ulcerative conditions from the mouth to the duodenum. The suspension comprises a pharmaceutically effec~ive amount of sucralfate and a pharmaceutically acceptable suspending agentO The suspen-sion must be one which is capable of forming a tacky, vis-cous mass when added to 0,2 to 1.0 N hydrochloric acid. The suspension may additionally contain bodying agents, preser-vatives, antifoam agents, flavors and coloring agents.
Detailed Descri tion of the Inven~ion This invention relates to a composition useful in the treatment of ulcers in the esophagus, stomach and duode-num, and possibly the mouth. Specifically, the invention is a suspension of a disaccharide polysulfate aluminum compound containing 7-13% sulfur and 11~24~ aluminum per molecule, such as sucralfate. The suspension is effective in the treatment not only of ulcers in the duodenum, but also of those from the mouth to the duodenum.
The invention will be described with specific ~5 reference to sucralfate. Ho~ever, it is understood that su~pen~ions of othPr ulcer treating agents disclosed and claimed in U.S. Patent No. 3,432l489 are encompassed within the present invention. That is, suspensions of disaccharide polysulfate-aluminum compounds containing 7 13~ sulfur and 11-24% aluminum per molecule are within the present inven-6~
1 I tion.
In preferred practice the composition of the in-vention is a suspension of sucralfate. ~he suspension is in I a form whiçh insures that sucralfate will react with any ulcer tissues with which it comes in contact after adminis-tration, i~ contrast to prior art sucralfate formulations in which sucralfate is not releas2d until it reaches the stom-ach and duodenum.
I The sucralfate suspension of the invention com-prises a pharmaceutically effective amount of sucralfate and a suspending agent which_is pharmaceutically acceptable.
Any suspension which will from a sticky viscous mass upon being combined with 0.2 ~o 1.~ N hydrochloric acid is ac-I ceptable for p~rposes of the invention.
lS ¦I The only limitations on the amounts and ~ypes of suspending agents useful in the practice of the inventionare 1) that they be pharmaceutically acceptable and 2) that ! when used with sucralfate, the resulting suspension forms a ¦, tacky viscous mass, which settles at least partially to the bottom of the reaction vessel~ upon addition to the hydro-chloric acid~ If, upon addition to hydrochloric acid the I particles remain suspended or there is no reaction~ the ¦ suspension is not acceptable for purposes of the present invention. The significance of the formation of the sticky ~5 mass is not ully understood. However, formulations of I sucralfate which have this characteristic provide sucralfate ¦ to any ulcer tissue with which the suspension comes in con-I tact after administration; that is the sucralfate is avail-11 able for reaction with ulcer tissues as soon as it passes I through the oral cavity.
1~
1 I The sucralfate suspensivn can be formulated from a ¦ wide range o suspending agents, including but not limited I to g~-ms, celluloses, clays and silicas and certain polymers.
I The following are representa~ive of pharmaceutically accept-able suspending agents which can be employed in this inven-tion: acacia, agar, alginic acid, carrageenan, guar, pec-tin, tragacanth, xanthan, carboxymethycellulose sodium, ~ hydroxypropyl cellulose, hydroxypropyl me~hylcellulose, j methylcellulose, microcrystalline cellulose, alum;num magne-¦, sium silicate, bentonite~ hectorit~, kaolin, silicon dioxide colloidal, and polyacrylic acid, polyvinyl alcohol, and I; polyvinylpyrrolidone polymers.
il The suspension may contain suspension adjuvants to improve patient acceptance and quality of the productO In-gredients such as (but not limited to) glycerin, sorbitol, ~l~ glucose, and sugar, can be added to increase the body of the suspension. Preservatives such as (but not limited to) I benzalkonium chloride, benzyl alcohol, parahydroxybenzoic ¦. acid esters, and sorbic acid and its salts can be a~ded to suppress growth o~ microoryanisms~ Antifoam agents such as the silicones can be added to dissipate foam produced when I the product is shaken prior to use. Finally~ flavors and j color may be added to improve palatibility.
~ In prefer~ed practice, sucralfate is formulated with microcrystalline cellulose, colloidal silicon dioxide and/or methyl cellulose as the suspending agent. ~he pre-I ferred formulation and variations thereof which are accept-¦l able for purposes of the present invention (i.e~, cause the ¦ appropri)te acid reaction) are as iollows:
I .
I ~
~8~
1 1~ ALLOWABLE
j INGREDI~NT ~ RANGES~ % W/V
¦, Sucralfate 10.00 1 to 60 Microcrystalline Cellulose NF 1.00 0 to 7 Colloidal Silicon Dioxide NF 0.20 0 to 5 Methylcellulose USP, 4000 cps 0.25 0 to 1 , Sorbitol 704 20000 0 to 60 ' Methylparaben 0.20 *
j Glycerin 99.5~ 9.90 0 to 40 Simethicone 30~ Emulsion 0.30 *
Water DI Filt. Q.S.
Total: 100.0 *Q.S~ to effective level.
In the above formulations~ the sorbitol and glyc-I
I erin are bodying agents; the methylparaben is a preserva-¦', tive; and the simethicone operates as an antifoaming agent.
The microcystalline cellulose, silicon dioxide and I methylcellulose are the suspending agents.
I In addition to the previously noted increased range of ulcers treatable by means of ~he invention, the I invention also provides a form of sucralfate suitable for administration via nasal-gastric tube to patients who cannot 1, swallow tablets.
I The following example is illustrative of the in-~ vention. Unless the context requires otherwise, all per-¦ centages in the examples and elsewhere in this application are weight percentages/volume.
1, li 1: 5 1 ` ~xample ~ he fQllo~ing compositions, which form a tacky viscous mass when added to 0.~ N hydro~hloric acid, are within the invention.
% W/V
INGREDIENT A B_ C
Sucralfate 10.0010~00 10.00 Methylcellulose 400 cps 0.75 Methylcellulose 4000 cps 1.50 Colloidal silicon disxidP 0.25 0~20 ¦ Microcrystalline celluloQe 1.00 1.00 , Alum;num magnesium silicate 1.00 I Methylparaben 0.12 0.15 0.15 ! Propylparaben 0.08 ! Glycer in Sorbitol 70% 40.00 20.00 20,00 ! Simethicone 30~ 0 30 I W~ter Q.S. Q.S. Q.S.
ll Il 1.
Il ~0 I' I'
1 SUCRAL~ATE SUSPENSION
Back~round of the Invention a~ Field of the Invention Sucralfate is a disaccharide polysulfate aluminum ~ompound useful in ~he trea~ment of duodenal ulsers. This invention provides a suspension of sucralfate by means of which sucralfate is made available for treatment of ulcer-, ~tive conditions of the esophagus and stomach, as well as the duodenum.
b) State of the Art Sucralfate is a disaccharide polysulfate aluminum compound which is covered by United States Patent No~
3,432,489. Sucralfate is believed to be 3,4,5,6-tetra-~polyhydroxyaluminum)-alpha~D-glycopyranosyl 1~ sulfate-2,3,4,5-tetra-(polyhydroxyaluminum)-beta-D-fructo-furanoside sulfate.
Sucralfate is useful in the treatment of ulcers in the duodenum. Sucralfate is available in tablets which . disintegrate rapidly in the stomach releasing the sucralfate , for reaction wlth ulcer tissues in the duodenum.
To date, sucralfate has not been available in a form which would render it effective in treatment of ulcer-ative conditions of the mouth, esophagus or stomachO The l; difficulty in formulating a sucralfate composition for ,, treatment of such sites has characteristically been due to the inability to supply sucralfate in a form which would be available at those sites. Formulations, including liquid formulations, have been tried without success.
~ It has now been discovered that sulcralfate is available for treatment of ulcer tissues in the esophagus 1 and stomach, as well as the duodenum, when formulated as a suspension which forms a sticky gel-like or ~acky viscous mass which settles ~o the bottom of ~he reaction vessel when added to 0.2 to 1.0 N hydrochloric acid.
Summary of he Invention This invention provides a sucralfate suspension effective for the treatment of ulcerative conditions from the mouth to the duodenum. The suspension comprises a pharmaceutically effec~ive amount of sucralfate and a pharmaceutically acceptable suspending agentO The suspen-sion must be one which is capable of forming a tacky, vis-cous mass when added to 0,2 to 1.0 N hydrochloric acid. The suspension may additionally contain bodying agents, preser-vatives, antifoam agents, flavors and coloring agents.
Detailed Descri tion of the Inven~ion This invention relates to a composition useful in the treatment of ulcers in the esophagus, stomach and duode-num, and possibly the mouth. Specifically, the invention is a suspension of a disaccharide polysulfate aluminum compound containing 7-13% sulfur and 11~24~ aluminum per molecule, such as sucralfate. The suspension is effective in the treatment not only of ulcers in the duodenum, but also of those from the mouth to the duodenum.
The invention will be described with specific ~5 reference to sucralfate. Ho~ever, it is understood that su~pen~ions of othPr ulcer treating agents disclosed and claimed in U.S. Patent No. 3,432l489 are encompassed within the present invention. That is, suspensions of disaccharide polysulfate-aluminum compounds containing 7 13~ sulfur and 11-24% aluminum per molecule are within the present inven-6~
1 I tion.
In preferred practice the composition of the in-vention is a suspension of sucralfate. ~he suspension is in I a form whiçh insures that sucralfate will react with any ulcer tissues with which it comes in contact after adminis-tration, i~ contrast to prior art sucralfate formulations in which sucralfate is not releas2d until it reaches the stom-ach and duodenum.
I The sucralfate suspension of the invention com-prises a pharmaceutically effective amount of sucralfate and a suspending agent which_is pharmaceutically acceptable.
Any suspension which will from a sticky viscous mass upon being combined with 0.2 ~o 1.~ N hydrochloric acid is ac-I ceptable for p~rposes of the invention.
lS ¦I The only limitations on the amounts and ~ypes of suspending agents useful in the practice of the inventionare 1) that they be pharmaceutically acceptable and 2) that ! when used with sucralfate, the resulting suspension forms a ¦, tacky viscous mass, which settles at least partially to the bottom of the reaction vessel~ upon addition to the hydro-chloric acid~ If, upon addition to hydrochloric acid the I particles remain suspended or there is no reaction~ the ¦ suspension is not acceptable for purposes of the present invention. The significance of the formation of the sticky ~5 mass is not ully understood. However, formulations of I sucralfate which have this characteristic provide sucralfate ¦ to any ulcer tissue with which the suspension comes in con-I tact after administration; that is the sucralfate is avail-11 able for reaction with ulcer tissues as soon as it passes I through the oral cavity.
1~
1 I The sucralfate suspensivn can be formulated from a ¦ wide range o suspending agents, including but not limited I to g~-ms, celluloses, clays and silicas and certain polymers.
I The following are representa~ive of pharmaceutically accept-able suspending agents which can be employed in this inven-tion: acacia, agar, alginic acid, carrageenan, guar, pec-tin, tragacanth, xanthan, carboxymethycellulose sodium, ~ hydroxypropyl cellulose, hydroxypropyl me~hylcellulose, j methylcellulose, microcrystalline cellulose, alum;num magne-¦, sium silicate, bentonite~ hectorit~, kaolin, silicon dioxide colloidal, and polyacrylic acid, polyvinyl alcohol, and I; polyvinylpyrrolidone polymers.
il The suspension may contain suspension adjuvants to improve patient acceptance and quality of the productO In-gredients such as (but not limited to) glycerin, sorbitol, ~l~ glucose, and sugar, can be added to increase the body of the suspension. Preservatives such as (but not limited to) I benzalkonium chloride, benzyl alcohol, parahydroxybenzoic ¦. acid esters, and sorbic acid and its salts can be a~ded to suppress growth o~ microoryanisms~ Antifoam agents such as the silicones can be added to dissipate foam produced when I the product is shaken prior to use. Finally~ flavors and j color may be added to improve palatibility.
~ In prefer~ed practice, sucralfate is formulated with microcrystalline cellulose, colloidal silicon dioxide and/or methyl cellulose as the suspending agent. ~he pre-I ferred formulation and variations thereof which are accept-¦l able for purposes of the present invention (i.e~, cause the ¦ appropri)te acid reaction) are as iollows:
I .
I ~
~8~
1 1~ ALLOWABLE
j INGREDI~NT ~ RANGES~ % W/V
¦, Sucralfate 10.00 1 to 60 Microcrystalline Cellulose NF 1.00 0 to 7 Colloidal Silicon Dioxide NF 0.20 0 to 5 Methylcellulose USP, 4000 cps 0.25 0 to 1 , Sorbitol 704 20000 0 to 60 ' Methylparaben 0.20 *
j Glycerin 99.5~ 9.90 0 to 40 Simethicone 30~ Emulsion 0.30 *
Water DI Filt. Q.S.
Total: 100.0 *Q.S~ to effective level.
In the above formulations~ the sorbitol and glyc-I
I erin are bodying agents; the methylparaben is a preserva-¦', tive; and the simethicone operates as an antifoaming agent.
The microcystalline cellulose, silicon dioxide and I methylcellulose are the suspending agents.
I In addition to the previously noted increased range of ulcers treatable by means of ~he invention, the I invention also provides a form of sucralfate suitable for administration via nasal-gastric tube to patients who cannot 1, swallow tablets.
I The following example is illustrative of the in-~ vention. Unless the context requires otherwise, all per-¦ centages in the examples and elsewhere in this application are weight percentages/volume.
1, li 1: 5 1 ` ~xample ~ he fQllo~ing compositions, which form a tacky viscous mass when added to 0.~ N hydro~hloric acid, are within the invention.
% W/V
INGREDIENT A B_ C
Sucralfate 10.0010~00 10.00 Methylcellulose 400 cps 0.75 Methylcellulose 4000 cps 1.50 Colloidal silicon disxidP 0.25 0~20 ¦ Microcrystalline celluloQe 1.00 1.00 , Alum;num magnesium silicate 1.00 I Methylparaben 0.12 0.15 0.15 ! Propylparaben 0.08 ! Glycer in Sorbitol 70% 40.00 20.00 20,00 ! Simethicone 30~ 0 30 I W~ter Q.S. Q.S. Q.S.
ll Il 1.
Il ~0 I' I'
Claims (3)
1. A pharmaceutical suspension comprising a pharmaceutically effective amount of a disaccharide polysulfate-aluminum compound containing 7-13% sulfur and 11-24% aluminum per molecule and a pharmaceutically accept-able suspending agent, said suspension being capable of forming a viscous mass when added to 0.2 to 1.0 N hydrochlo-ric acid.
2. The composition of Claim 1 wherein the disac-charide compound is sucralfate.
3. The composition of Claim 2 wherein the sus-pending agent is selected from the group consisting of gums, celluloses, clays, silicas and vinyl and acrylic polymers.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52897683A | 1983-09-02 | 1983-09-02 | |
| US06/528,976 | 1983-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1218601A true CA1218601A (en) | 1987-03-03 |
Family
ID=24108004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000461033A Expired CA1218601A (en) | 1983-09-02 | 1984-08-15 | Sucralfate suspension |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0136100B1 (en) |
| AT (1) | ATE78691T1 (en) |
| AU (1) | AU564201B2 (en) |
| CA (1) | CA1218601A (en) |
| DE (1) | DE3485843T2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4945084A (en) * | 1987-07-08 | 1990-07-31 | Norman Oksman | Method and composition for topically treating anorectal or other dermal wounds |
| US7175855B1 (en) | 1999-05-27 | 2007-02-13 | Pfizer Inc. | Ziprasidone suspension |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3430809A1 (en) * | 1984-08-22 | 1986-03-06 | Merck Patent Gmbh, 6100 Darmstadt | SUCRALFAT SUSPENSION |
| DK164199C (en) * | 1986-05-16 | 1992-10-19 | Chugai Pharmaceutical Co Ltd | SUCRALPHATE PREPARATION FOR USE ON OESOPHAGUS MUCOSA |
| US5916880A (en) * | 1987-12-21 | 1999-06-29 | Bukh Meditec A/S | Reduction of skin wrinkling using sulphated sugars |
| DK505488D0 (en) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | MEDIUM AND USE OF SAME |
| DK505588D0 (en) * | 1988-02-26 | 1988-09-09 | Jesper Hamburger | MEDIUM AND USE OF SAME |
| US5709873A (en) * | 1988-02-26 | 1998-01-20 | Niels Bukh A/S | Method of treating conditions of teeth and their supporting tissue |
| JP2735559B2 (en) * | 1988-03-02 | 1998-04-02 | 中外製薬株式会社 | Suspension |
| EP0348143A3 (en) * | 1988-06-21 | 1991-03-13 | MARION LABORATORIES, INC. (a Delaware corporation) | Bismuth derivatives of saccharide phosphates and sulphates |
| US4918175A (en) * | 1988-06-21 | 1990-04-17 | Marion Laboratories, Inc. | Bismuth (phosph/sulf)ated saccharides |
| US4975281A (en) * | 1989-01-30 | 1990-12-04 | E. R. Squibb & Sons, Inc. | Anti-ulcer composition |
| US5618798A (en) * | 1989-04-20 | 1997-04-08 | Bar-Shalom; Daniel | Use of sucralfate to treat baldness |
| GR1000796B (en) * | 1989-08-25 | 1992-12-30 | Bukh Meditec | Method for dental disease treatment |
| IE903302A1 (en) * | 1989-09-15 | 1991-04-10 | Pehrom Pharmaceutical Corp | Topical preparation for treatment of aphthous ulcers and¹other lesions |
| AU689366B2 (en) * | 1995-02-02 | 1998-03-26 | Chugai Seiyaku Kabushiki Kaisha | Sucralfate preparation |
| KR19980703526A (en) * | 1995-04-03 | 1998-11-05 | 나가야마오사무 | Sucralate-containing formulation composition |
| EP1681065A4 (en) * | 2003-10-31 | 2011-12-28 | Wakamoto Pharma Co Ltd | WATER-BASED COMPOSITION WITH REVERSIBLE THERMALIZATION |
| FR2927808B1 (en) * | 2008-02-26 | 2011-04-29 | Fabre Pierre Dermo Cosmetique | STERILIZED SUCRALFATE GEL |
| GR1008308B (en) | 2013-05-31 | 2014-10-02 | UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", | Local pharmaceutical and medi-tech compositions containing combinations of sucralfat, hyaluronic acid, arginine and one natural moistening factor |
| CN116763728A (en) * | 2022-03-11 | 2023-09-19 | 北京阳光诺和药物研究股份有限公司 | Gastric acid neutralizing medicine and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3432489A (en) * | 1965-11-05 | 1969-03-11 | Chugai Pharmaceutical Co Ltd | Disaccharide polysulfate aluminium compound and method |
| JPS5978116A (en) * | 1982-10-27 | 1984-05-04 | Chugai Pharmaceut Co Ltd | Pharmaceutical preparation of sucralfate |
| DE3322078A1 (en) * | 1983-06-20 | 1984-12-20 | Merck Patent Gmbh, 6100 Darmstadt | USE OF SUCRALFATE FOR CONTROLLING EMESIS AND / OR DIARRHOE |
-
1984
- 1984-08-15 CA CA000461033A patent/CA1218601A/en not_active Expired
- 1984-08-24 AU AU32361/84A patent/AU564201B2/en not_active Ceased
- 1984-08-29 DE DE8484305891T patent/DE3485843T2/en not_active Expired - Lifetime
- 1984-08-29 AT AT84305891T patent/ATE78691T1/en not_active IP Right Cessation
- 1984-08-29 EP EP84305891A patent/EP0136100B1/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4945084A (en) * | 1987-07-08 | 1990-07-31 | Norman Oksman | Method and composition for topically treating anorectal or other dermal wounds |
| US7175855B1 (en) | 1999-05-27 | 2007-02-13 | Pfizer Inc. | Ziprasidone suspension |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE78691T1 (en) | 1992-08-15 |
| DE3485843T2 (en) | 1992-12-10 |
| AU3236184A (en) | 1985-03-07 |
| EP0136100B1 (en) | 1992-07-29 |
| DE3485843D1 (en) | 1992-09-03 |
| EP0136100A2 (en) | 1985-04-03 |
| AU564201B2 (en) | 1987-08-06 |
| EP0136100A3 (en) | 1986-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1218601A (en) | Sucralfate suspension | |
| EP0138540B1 (en) | Pharmaceutical compositions | |
| US4788220A (en) | Pediatric ibuprofen compositions | |
| CA2179682C (en) | Pharmaceutical, orally applicable composition | |
| FI92060B (en) | Process for the preparation of ranitidine resin adsorbate | |
| CA2323680A1 (en) | Orally disintegrable tablets | |
| EP0620001A1 (en) | Aqueous pharmaceutical suspension and process for preparation thereof | |
| US5498426A (en) | Liquid antacid compositions | |
| MXPA97002456A (en) | Liquid antiacidal compositions containing calcium carbonate and possibly simeticone as active compounds and monobasic potassium phosphate and potassium bicarbonate as regula | |
| US4704278A (en) | Fluidized magaldrate suspension | |
| NZ204974A (en) | Thickened aqueous sodium fluoride compositions for dental care | |
| WO1993017679A1 (en) | Compositions containing ranitidine/bismuth carboxylates salts | |
| EP0715520B1 (en) | Use of a suspension based on sucralphate gel as antacid | |
| EP0248740A2 (en) | A composition of aluminium hydroxide gel | |
| JPS5942318A (en) | Therapeutical composition, manufacture and use | |
| GB2090134A (en) | Pharmaceutical Compositions Containing Guaiacol or Derivatives Thereof | |
| JP3364453B2 (en) | Sennoside-containing aqueous solution | |
| CA1252045A (en) | Fluidized magaldrate suspension | |
| KR100192016B1 (en) | An oral composition in solution form | |
| JPS647967B2 (en) | ||
| GB2049418A (en) | Pharmaceutical antacid compositions | |
| PT835653E (en) | LIQUID ANTI-LIQUID COMPOSITIONS | |
| JPH06183972A (en) | Aqueous pharmaceutical preparation containing aldioxa | |
| JPS61263920A (en) | Medicinal composition | |
| IE831267L (en) | Compostions containing salbutamol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |